Rare disease genomic diagnostics with FDA-cleared exome and genome sequencing
GeneDx operates a clinical genomics lab and diagnostic platform focused on rare disease identification through whole exome and genome sequencing. The company is scaling sales-first, with leadership and senior account roles dominating hiring and a concentrated push into NICU (neonatal intensive care) adoption—suggesting a shift from reactive rare-disease testing toward preventive newborn screening as a growth vector. Their tech stack (Snowflake, LIMS, Epic integration, React/Python backend) reflects clinical-grade data infrastructure paired with hospital workflow embedding.
Notable leadership hires: Product Lead, Regional Sales Director, Sales Director, Account Director, Strategic Account Director
GeneDx provides genomic diagnostic testing for rare genetic disorders, operating one of the largest rare disease genomic datasets (GeneDx Infinity™). The company performs whole exome and whole genome sequencing tests (ExomeDx™ and GenomeDx™) for clinical providers, with FDA Breakthrough Device Designation. They serve hospitalized and outpatient populations, with active expansion into neonatal screening. The organization spans 1,001–5,000 employees across sales, clinical operations, and data functions, headquartered in Stamford, CT.
Snowflake for data warehousing, LIMS for lab information management, Epic Systems for clinical integration, React/Python/TypeScript for application layers, and Tableau/Power BI for analytics and reporting.
Yes. Active projects include adoption of exome and genome sequencing in NICU, NICU market growth, and educational initiatives for NICU teams—indicating expansion into newborn screening as a strategic priority.
Other companies in the same industry, closest in size